1. |
de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes[J]. Prog Retin Eye Res, 2011, 30(6): 452-470. DOI: 10.1016/j.preteyeres.2011.06.005.
|
2. |
Karim R, Sykakis E, Lightman S, et al. Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis[J]. Clin Ophthalmol, 2013, 7: 1109-1144. DOI: 10.2147/OPTH.S40268.
|
3. |
McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis[J]. BMJ, 2000, 320(7234): 555-558. DOI: 10.1136/bmj.320.7234.555.
|
4. |
Sangwan VS, Pearson PA, Paul H, et al. Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population[J]. Ophthalmol Ther, 2015, 4(1): 1-19. DOI: 10.1007/s40123-014-0027-6.
|
5. |
Brady CJ, Villanti AC, Law HA, et al. Corticosteroid implants for chronic noninfectious uveitis[J/OL]. Cochrane Database Syst Rev, 2016, 2(2): CD010469[2016-02-12]. http://europepmc.org/article/MED/26866343. DOI: 10.1002/14651858.
|
6. |
Urkholder BM, Moradi A, Thorne JE, et al. The dexamethasone intravitreal implant for noninfectious uveitis: practice patterns among uveitis specialists[J]. Ocul Immunol Inflamm, 2015, 23(6): 444-453. DOI: 10.3109/09273948.2015.1070180.
|
7. |
Whitcup SM, Robinson MR. Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis[J]. Ann N Y Acad Sci, 2015, 1358: 1-12. DOI: 10.1111/nyas.12824.
|
8. |
Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant[J]. Invest Ophthalmol Vis Sci, 2011, 52(1): 80-86. DOI: 10.1167/iovs.10-5285.
|
9. |
Khurana RN, Porco TC. Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema[J]. Retina, 2015, 35(8): 1640-1646. DOI: 10.1097/iae.0000000000000515.
|
10. |
Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency[J]. Am J Ophthalmol, 2014, 158(6): 1136-1145. DOI: 10.1016/j.ajo.2014.09.003.
|
11. |
Ryder SJ, Iannetta D, Bhaleeya SD, et al. Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion[J]. Clin Ophthalmol, 2015, 9: 1109-1116. DOI: 10.2147/opth.S84207.
|
12. |
Rossetto JD, Nascimento H, Fernandes DD. Treatment of cystoid macular edema secondary to chronic non-infectious intermediate uveitis with an intraocular dexamethasone implant[J]. Arq Bras Oftalmol, 2015, 78(3): 190-193. DOI: 10.5935/0004-2749.20150049.
|
13. |
Yap YC, Papathomas T, Kamal A. Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in non-infectious posterior uveitis[J]. Int J Ophthalmol, 2015, 8(4): 835-838. DOI: 10.3980/j.issn.2222-3959.2015.04.34.
|
14. |
Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis[J]. Ophthalmology, 2014, 121(8): 1649-1654. DOI: 10.1016/j.ophtha.2014.02.003.
|
15. |
Nobre-Cardoso J, Champion E, Darugar A, et al. Treatment of non-infectious uveitic macular edema with the intravitreal dexamethasone implant[J]. Ocul Immunol Inflamm, 2017, 25(4): 447-454. DOI: 10.3109/09273948.2015.1132738.
|
16. |
Adán A, Pelegrín L, Rey A, et al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients[J]. Retina, 2013, 33(7): 1435-1440. DOI: 10.1097/IAE.0b013e31827e247b.
|
17. |
Pohlmann D, Vom Brocke GA, Winterhalter S, et al. Dexamethasone inserts in noninfectious uveitis: a single-center experience[J]. Ophthalmology, 2018, 125(7): 1088-1099. DOI: 10.1016/j.ophtha.2017.12.038.
|
18. |
Yalcinbayir O, Caliskan E, Ucan Gunduz G, et al. Efficacy of dexamethasone implants in uveitic macular edema in cases with behçet disease[J]. Ophthalmologica, 2019, 241(4): 190-194. DOI: 10.1159/000490674.
|
19. |
Tsang AC, Virgili G, Abtahi M, et al. Intravitreal dexamethasone implant for the treatment of macular edema in chronic non-infectious uveitis[J]. Ocul Immunol Inflamm, 2017, 25(5): 685-692. DOI: 10.3109/09273948.2016.1160130.
|
20. |
Khurana RN, Bansal AS, Chang LK, et al. Prospective evaluation of a sustained-release dexamethasone intravitreal implant for cystoid macular edema in quiescent uveitis[J]. Retina, 2017, 37(9): 1692-1699. DOI: 10.1097/iae.0000000000001406.
|
21. |
王珂欣, 朱瑞琳. 杨柳. 眼底自身荧光在非感染性葡萄膜炎中的应用研究现状及进展[J]. 中华眼底病杂志, 2018, 34(1): 92-95. DOI: 10.3760/cma.j.issn.1005-1015.2018.01.028.Wang KX, Zhu RL, Yang L. The status and advances in the application of fundus autofluorescence in noninfectious uveitis[J]. Chin J Ocul Fundus Dis, 2018, 34(1): 92-95. DOI: 10.3760/cma.j.issn.1005-1015.2018.01.028.
|
22. |
Frère A, Caspers L, Makhoul D, et al. Single dexamethasone intravitreal implant in the treatment of noninfectious uveitis[J]. J Ocul Pharmacol Ther, 2017, 33(4): 290-297. DOI: 10.1089/jop.2016.0139.
|
23. |
Taylor SR, Banker A, Schlaen A, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis[J]. Retina, 2013, 33(10): 2149-2154. DOI: 10.1097/IAE.0b013e31828ac07d.
|
24. |
Shah KK, Majumder PD, Biswas J. Intravitreal therapeutic agents in noninfectious uveitic macular edema[J]. Indian J Ophthalmol, 2018, 66(8): 1060-1073. DOI: 10.4103/ijo.IJO_35_18.
|